Back to Search
Start Over
Assessment of adherence to at-home oral anti-infective therapy among paediatric patients discharged from a Quebec hospital
- Source :
- European Journal of Hospital Pharmacy : Science and Practice; 2023, Vol. 30 Issue: 1 p35-40, 6p
- Publication Year :
- 2023
-
Abstract
- ObjectivesNon-adherence to anti-infective therapy contributes to treatment failure and the emergence of bacterial resistance. This study aimed to assess at-home adherence, by paediatric patients, to oral anti-infective (OAI) therapy prescribed for treatment of acute infections and to explore the factors contributing to non-adherence.MethodsThis prospective descriptive study involved French-speaking patients under 16 years of age who were discharged with one or more OAIs prescribed for home administration for a maximum of 30 days. Telephone surveys were used to assess overall adherence, which consisted of primary adherence (patient’s ability to procure the medication) and secondary adherence (patient’s ability to take the treatment as prescribed).ResultsOverall, 51.7% (30/58) of patients were adherent to OAI therapy, with 100% primary adherence (n=69/69) and 51.7% secondary adherence (n=30/58). On average, patients took 98% of the total number of doses prescribed, and non-adherence was related mostly to not following medication administration schedules (63.3% of patients followed the exact schedule). Indeed, the adherence rate for patients taking one or two doses per day was twice the rate for patients taking more than two doses per day (81.8% vs 44.7%, p=0.043).ConclusionsHalf of the paediatric patients treated for acute infections were non-adherent to OAI therapy at home. Interventions are needed to improve this situation.
Details
- Language :
- English
- ISSN :
- 20479956 and 20479964
- Volume :
- 30
- Issue :
- 1
- Database :
- Supplemental Index
- Journal :
- European Journal of Hospital Pharmacy : Science and Practice
- Publication Type :
- Periodical
- Accession number :
- ejs61462750
- Full Text :
- https://doi.org/10.1136/ejhpharm-2020-002656